Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 2/20 | 0.33 |
| ▸ | PGK2 | P07205 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL2722872 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL2639135 | 1.00 | KDM4E (0.43) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL5797703 | 1.00 | KDM4E (0.43) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL26923466 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL3436971 | 0.95 | KDM4E (0.40) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL6538439 | 0.95 | KDM4E (0.40) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL28998696 | 0.95 | KDM4E (0.40) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL28998089 | 0.91 | CA2 (0.43) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL29005726 | 0.88 | CA2 (0.40) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Benzene SCHEMBL3437104 | 0.88 | CFTR (0.39) | KDM4EMMP2THRBMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005508297-A | — | — | 2005-03-31 | — | — | JP | claimed |
| WO-2003000056-A1 | JOINT LUBRICATION WITH P2Y PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-20110282044-A1 | PROCESS FOR SYNTHESIZING OLIGONUCLEOTIDE PHOSPHATE DERIVATIVES | ALNYLAM PHARMACEUTICALS (US) | 2011-11-17 | — | — | US | disclosed |
| US-8008274-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| EP-1450820-A4 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | INSPIRE PHARMACEUTICALS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1786441-A2 | METHOD AND MEANS FOR ENHANCED PULMONARY DRUG DELIVERY | University College Cardiff Consultants, Ltd. (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006016115-A2 | METHOD AND MEANS FOR ENHANCED PULMONARY DRUG DELIVERY | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1450820-A2 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | Inspire Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | PETERSON WARD M (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003039473-A2 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | KDM4E 1716/4885MMP2 3131/4885THRB 4461/4885 |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | ADORA2B, ADORA2A, P2RY2 | KDM4E 4578/4885MMP2 1134/4885THRB 3183/4885 |
| US-20110282044-A1 | PROCESS FOR SYNTHESIZING OLIGONUCLEOTIDE PHOSPHATE DERIVATIVES | PPA1, TYMP, DCTPP1 | KDM4E 2324/4885MMP2 3049/4885THRB 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.